Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Charles River Laboratories International, Inc. (CRL) vs Guardant Health, Inc. (GH)

Charles River Laboratories International, Inc. and Guardant Health, Inc. are both Diagnostics & Research companies. Guardant Health, Inc. is the larger, with a market value of $23.9B against $14.1B — 1.7× the size. Guardant Health, Inc. grew revenue faster over the last twelve months: 42.7% against −0.74%. Charles River Laboratories International, Inc. has the higher net margin (−5.96% vs −38.3%) and the higher return on invested capital (1.07% vs −129.7%). Across the 17 metrics below, Charles River Laboratories International, Inc. leads on 9 and Guardant Health, Inc. on 8.

Valuation

Metric CRL GH Diagnostics & Research median
P/E n/m n/m 33.95
P/S 3.52 19.91 4.87
P/B 4.94 n/m 3.12
Price to free cash flow 37.94 n/m 34.02
EV/EBITDA 29.82 n/m 25.20
EV/Sales 4.12 20.29 5.66
Earnings yield (1.65%) (1.97%) (1.75%)
Free cash flow yield 2.64% (1.10%) (0.13%)

Profitability

Metric CRL GH Diagnostics & Research median
Gross margin 32.67% 65.01% 50.89%
Operating margin 2.25% (39.75%) (8.57%)
Net margin (5.96%) (38.33%) (6.37%)
Free cash flow margin 9.27% (20.35%) 0.00%
Return on equity (7.69%) 171.64% (2.92%)
Return on assets (3.16%) (27.95%) (6.71%)
Return on invested capital 1.07% (129.70%) 0.00%

Growth

Metric CRL GH Diagnostics & Research median
Revenue growth (TTM) (0.74%) 42.74% 7.69%
EPS growth (last fiscal year) (1,555.00%) 6.74% —
Revenue growth, 5-year CAGR 6.55% 27.92% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRL GH Diagnostics & Research median
Debt to equity 0.92 (6.74) 0.11
Current ratio 1.35 4.03 2.02
Net debt to EBITDA 3.24 (0.75) 0.78

Dividend

Metric CRL GH Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric CRL GH Diagnostics & Research median
Market cap 14.09b 23.94b 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack